CVI Quarterly

The Stanford Cardiovascular Institute (CVI) is pleased to an-nounce the appointment of Richard Lawn, PhD, as CVI Con-

sulting Professor effective Nov. 1, 2013.

Richard Lawn received a B.A. degree in astronomy from Harvard College and a PhD in molecular, cellular and devel-opmental biology from the University of Colorado. His post-doctoral research un-der Tom Maniatis at Caltech featured the construction of the first human genomic DNA library and the isolation and cloning of the globin genes.

As a senior scientist for ten years at Genentech, his laborato-ry cloned and characterized a number of important genes and

Richard Lawn, PhD, Joins CVI

Fall 2013Cardiovascular Institute

In This Issue:New Chair of CT Surgery page 1-2Richard Lawn, PhD page 1-2Exercise ‘Prescription’ page 3Cancer Drug Might Help Diabetes page 3Athlete Dives in After Surgery page 4Virus Barometer of Immune System page 5Determing How Proteins Govern Genes page 5CVI Clinical Trial Manager page 6Recruiting for ixCell DCM and PACE trials page 6CVI Newsbeats page 7-8CVI Members at AHA page 8CVI Postdoc Travel Awards page 8CVI Seed Grant Recipients page 9CVI Frontiers Seminars / Recruiting page 10 CVI Publications page 11-13Upcoming Grants / Postdoctoral Awards page 14Upcoming Meetings page 15CVI Leadership page 16

1

LAWN continues on p. 2

BY TRACIE WHITE

Y. Joseph Woo, MD, a nationally rec-ognized heart surgeon and leading researcher in new approaches to car-diovascular care, has been appointed chair of the De-partment of Cardiothoracic Surgery at the Stanford Uni-versity School of Medicine. He will start Jan. 1.

“Joe is an exceptional re-searcher, clinician and ed-ucator, who will lead our distinguished Department of Cardio-thoracic Surgery to new levels of excel-lence,” said Lloyd Minor, MD, dean of the School of Medicine. “Stanford Medicine is fortunate to have been able to recruit someone with his talents and vision.”

Philip Oyer, MD, the Roy B. Cohn-The-odore A. Falasco Professor of Cardio-thoracic Surgery, has been acting as

interim department chair since the former chair, Robert Robbins, MD, left Stanford a year ago to head up the Tex-as Medical Center in Houston.

Amir Dan Rubin, president and CEO of Stanford Hospi-tal & Clinics, said, “We are so thrilled to welcome Dr. Woo to Stanford, as he has been an innovator in advancing the leading edge of cardiac care while delivering highly co-ordinated, patient-centered

care. Dr. Woo not only has built world-class programs, but has been a role model for treating patients with caring, compassion and consideration — what we at Stanford call C-I-CARE.”

Woo, 46, is currently a professor of surgery at the University of Pennsylva-nia, where he has been on the faculty since 2002 and directs the Minimally

Invasive and Robotic Cardiac Surgery Program and the Cardiac Transplanta-tion and Mechanical Circulatory Sup-port Program.

He has led a successful career in the operating room, classroom and labora-tory. As a surgeon who performs 350 to 400 heart surgeries a year, he has built a thriving clinical practice, pioneering multiple, innovative procedures, in-cluding minimally invasive techniques for mitral and aortic valve repair and reconstruction.

His research encompasses basic, translational and clinical projects. His laboratory, funded by the National Institutes of Health, investigates new paths to myocardial repair through angiogenesis — the process through which new blood vessels form from pre-existing vessels — stem cells and

Y. Joseph Woo

New Chair of Cardiothoracic Surgery Named

Richard Lawn

WOO continues on p. 2

www.cvi.st

CVI Quarterlyanford.edu all F 2013

LAWN from p. 1

2

CVI Quarterly is a newsletter that showcases the academic and re-search activities of the Stanford Cardiovascular Institute’s members

CVI Quarterly Editorial Team

265 Campus Drive, G1120, MC-5454, Stanford, CA 94305Phone: 650-725-7964; http://cvi.stanford.edu

Articles marked with z reprinted with permission fromStanford’s Office of Communication & Public Affairs

Articles marked with v reprinted with permission from Stanford Hospital & Clinics Office of Communications

Janet Kalesnikoff David L. M. Preston

Newsletter EditorCVI Associate Director

Newsletter Copy-editorCVI Program Manger

jkalesni@stanford.edu preston@stanford.edu

their recombinant proteins in the fields of hemostasis and atherosclerosis, including clotting factor VIII (now a standard treatment for hemophelia), anti-thrombin III, LCAT, CETP and Lp(a).

Dr. Lawn then served as a Professor of Cardiovascu-lar Medicine at Stanford and Vice President, Discov-ery Research at CV Therapeutics, where he used the emerging techniques of RNA profiling to identify the defect in Tangier disease to reveal the role of the lipid transporter ABCA1 in the HDL cholesterol pathway.

Dr. Lawn has also worked with biotech companies in the development of novel diagnostics using RNA profiling and proteomics. He continues his interest in joining basic research with biotech commitment to translate biomedical research into drug and diagnos-tic application.

For more: http://tinyurl.com/kzzcxez.

tissue engineering. As an educator, he has mentored many future surgeons.

“Some of the most famous people in cardiac surgery have led the pro-gram at Stanford over the years,” Woo said, citing the late Norman Shumway, MD, who performed the first successful heart transplant in the United States at Stanford in 1968. “It’s truly a privilege to become a part of this amazingly presti-gious, high-powered academic institu-tion.”

Woo said he hopes to continue that tradition of excellence and innovation, furthering basic research in the lab and bringing basic science discoveries into use in clinical trials. He has run several clinical trials involving the translational use of stem cells for treatment of heart disease, and said he hopes to see Stan-ford’s participation in clinical trials at the national level increase.

He plans to lead exploration of the newest techniques and devices for heart care, such as innovative ap-proaches to valve repair; smaller, more efficient mechanical heart pumps; and operations performed without stop-ping the heart.

Woo, who was born in Missouri and raised in New Jersey, earned a bach-elor’s degree from the Massachusetts Institute of Technology and a medical degree from the University of Pennsyl-vania, where he conducted his post-graduate surgical training. Woo also completed a postdoctoral research fel-

lowship in novel molecular strategies for attenuating myocardial ischemic injury, for which he won the American Heart Association Vivien Thomas Young Investigator Award.

Woo joined the Penn faculty in 2002 as the director of the Minimally Invasive Cardiac Surgery Program. He has ad-vanced the field of complex valve repair and serves as principal investigator for several clinical device trials and trans-lational scientific clinical trials, such as delivering stem cells during coronary artery bypass grafting and mechanical heart pump implantation.

“Apart from the name confusion, I’m very excited Joe is coming,” joked Jo-seph C. Wu, MD, PhD, whose name is pronounced the same as Woo’s.

“I think he epitomizes the rare breed of cardiothoracic surgeon who’s a triple threat,” said Wu, professor of cardiovas-cular medicine and of radiology, and director of the Stanford Cardiovascular Institute. “He excels at academic med-icine. Clinically, he’s world-renowned in mitral valve repair and the use of mechanical devices. From a research perspective, he’s one of the few CT sur-geons I know who has continuous NIH funding. As an educator, he is passion-ate in training the next generation of thought leaders in CT surgery.”

“I’m looking forward to working closely with him to take the Stanford Cardiovascular Institute and cardiotho-racic surgery to the highest level — to be internationally recognized as the best program in the world.”

Woo is married and has two teenage children. z

For more: http://tinyurl.com/k2vmqn8 and http://tinyurl.com/mpd-keca.

WOO from p. 1

‘I think he epitomizes the rare breed of cardio-thoracic surgeon who’s a

triple threat.’

By MICHELLE BRANDT

Two recently-published studies provide new insight on diabetes and show how a cancer drug was used to treat the disorder in animal models.

The studies, done in mice, identify a previously unex-pected link between a low-oxygen condition called hypox-ia and the ability of cells in the liver to respond to insulin. The drug, aflibercept (marketed as Eylea or Zaltrap), is used to treat metastatic colorectal cancer and a form of macular degeneration. Aflibercept is a member of a fami-ly of proteins that inhibit the vascular endothelial growth factor, or VEGF, pathway. It works by blocking the growth of the blood vessels into tumors and starving them of ox-ygen.

The lab of Calvin Kuo, MD, PhD, professor of medicine, identified a series of protein interactions that link VEGF inhibitors and blood glucose levels. “We were surprised

to find that this drug currently used in patients for cancer treatment had beneficial effects on diabetes in laboratory mice and could, potentially, in humans,” said Kuo, senior author of one of the Nature Medicine papers.

Together, the studies explain an observation made several years ago by Kuo and his lab members that VEGF inhibitors, such as aflibercept, could lower blood glucose levels in mice. There have been intriguing hints that these inhibitors could function in a similar way in humans, but human studies have not been formally conducted. z

For more: http://tinyurl.com/n4hxvtc.

3

Cancer Drug Appears Helpful for Diabetes

Link to full articles inNature Medicine:

http://tinyurl.com/ougcsu8 and http://tinyurl.com/ooh74og

Exercise as a Better Heart ‘Prescription’By MOLLY SHARLACH

A recent six-nation survey from the World Heart Organization showsthat a majority of adults walk for less than half an hour each day. This year’s World Heart Day’s (Sept. 29) theme was changing lifestyles to prevent and control cardio-vascular disease, the num-ber one cause of death in the United States and world-wide.

Both common sense and medical science increas-ingly point to regular phys-ical activity as a simple and effective way to decrease the risk of cardiovascular disease and a host of other ailments. But what about pa-tients who have already had a stroke or heart failure, or those with coronary heart disease or prediabetes? Can ex-ercise help keep these patients alive? How do the outcomes of exercise inter-ventions compare with those of drug treatments?

Stanford professor John Ioannidis, MD, DSc, addresses these questions in a meta-analysis published in the Brit-ish Medical Journal. In collaboration with Huseyin Naci, a researcher and fellow at the London School of Eco-nomics and Harvard Medical School,

Ioannidis culled data from more than 300 clinical tri-als, representing more than 300,000 individual patients. Ioannidis and Naci com-pared the effectiveness of exercise with various drug interventions to prevent mortality for patients recov-ering from stroke or heart

failure, as well as those with coronary heart disease or prediabetes.

For patients with coronary heart dis-ease or prediabetes, exercise and drug interventions appeared to have simi-lar effects on mortality. However, for those recovering from a stroke, exer-cise led to better outcomes than drugs, while for those with previous heart fail-ure, diuretics in particular prevented

deaths more effectively than exercise or other drugs.

Still, Ioannidis and Naci emphasize that not enough trials have been done on the mortality benefits of exercise – only 57 of the 305 trials they analyzed included exercise interventions – and that in future trials, exercise should be directly compared to drug treatments.

While Centers for Disease Control and Prevention statistics show that about one-third of primary care physicians prescribe an “exercise pill” to their pa-tients, these prescriptions may be more effective when supervised by a reha-bilitation program. “Exercise has been quite neglected to-date,” Ioannidis told me. “There is plenty of room to reap more benefits from something that is both effective and enjoyable. The pen-dulum may need to swing back [from drug treatments to lifestyle interven-tions] for many reasons, including the intolerable cost of many medications and their potential toxicities.” z

For more: http://tinyurl.com/mlcut7r.

John Ioannidis

4

By SARA WYKES

Thoracic outlet syndrome (TOS) would make Taylor Sishc’s left arm feel numb and weak. He underwent surgery at Stan-ford to treat the condition.

Sishc, an All-American high school diver recruited to Stan-ford University’s elite team, had received prompt attention from the team’s trainers and sports medicine doctors, but until he was referred to Stanford Hospital & Clinics’ vascular sur-geon Jason Lee, MD, he didn’t really know what was going on with his arm.

Lee, an associate professor of surgery at the School of Med-icine, had his suspicions about what the problem was: Sishc might have thoracic outlet syndrome (TOS), a condition often seen in athletes but also found in people who use their arms in a repetitive motion, which can lead to the compression of nerves or blood vessels, or both, in the thoracic outlet — an area bounded by the base of the neck and the first rib.

Sishc had been a gymnast since childhood and a serious competitive diver since he was 13. By the time he reached Stanford, he had been lifting his arms over his head in a similar motion for years — exactly the kind of long-term overuse that creates thoracic outlet syndrome.

The tricky part about TOS, Lee said, is not just making the diagnosis. Trainers, therapists and sur-geons have worked on TOS treatment for

decades with results that were not always consistent. In a 2010 paper published in the Journal of Vascular Surgery, Lee and his colleagues presented a review of nine years of Stanford TOS patients that showed that a specific set of steps for work-up and surgical intervention increased successful outcomes for TOS operations from 50 percent to nearly 90 percent.

Lee asked Sishc to begin a six- to eight-week course of phys-ical therapy of what’s called the Edgelow protocol. It’s a series of movements and breathing and posture adjustments de-signed to alter the compressed space of muscles and bones that causes TOS.

What his research had shown was that patients who im-proved completely with the therapy obviously wouldn’t need the surgery and that those who didn’t respond at all probably wouldn’t be helped by further anatomical reconfiguration. Those who were helped initially and then plateaued would be the best candidates for what Lee calls “the ultimate decom-pression of the nerve, the ultimate space clearing.”

Lee wanted to determine, before making a decision about surgery, to what extent such exercises would help Sishc. Sur-gery would mean the permanent removal of his first rib to

reduce pressure on the compressed nerves. Sishc had never heard of TOS before his diagnosis; he was surprised at the pos-sible surgical solution. Sishc began diligently doing the Edge-low exercises.

The therapy did help — until it didn’t. That was exactly what Lee was expecting in the high-performing athlete. Lee went in and removed Sishc’s first rib. The surgery was followed by months of rest for Sishc’s arm, physical therapy and a gradual return to his sport. “It was a lot easier than I expected it to be,” Sishc said. By the time he was given the go-ahead to dive again,

he’d been out of the water for six months.

Finally, he was allowed to train again. “We took it very slow,” Sishc said, “and my first meets were a little rough. For a year, I struggled with getting strong and getting

everything back to where it was. I didn’t expect to make the NCAA championships.” But his old form came back. In Janu-ary 2012, as a Stanford senior, he helped his team win the an-nual Stanford Diving Invitational — taking the top spot in five of six dives he made from the competition’s highest platform, the 10-meter.

Last March Sishc qualified for the NCAA national diving championships, winning a chance to compete against the na-tion’s very best divers. “I honestly did not think I was going to get back up there. So it was a great feeling to say that I did it,” Sishc said. “I also knew that it wouldn’t have been possible without the medical team here at Stanford, especially Dr. Lee.”

Sishc made the top group of finishers in the 3-meter spring-board, as well as in the 10-meter platform he once thought he’d never see again, to become a collegiate Division 1 All-American in two events. v

For more: http://tinyurl.com/p5x25no and http://tinyurl.com/pzrfj66.

Cardinal Athlete Dives Back in After Surgery

Taylor SishcPhoto: Todd Holland

The therapy did help— until it didn’t.

BY KRISTA CONGER

In a recent study published in Cell, by Stanford geneticist Michael Snyder, PhD, he and his colleagues outlined an entirely new way to determine how pro-teins that govern gene expression inter-act with DNA and with one another. The technique allows them to track the in-teractions of hundreds of factors simul-taneously and track how a cell responds to complex environmental and devel-opmental cues. Previously researchers have been restricted to following just two or three molecules at a time.

“At a very basic level, we are learning who likes to work with whom to regu-late around 20,000 human genes,” said Snyder. “If you had to look through all possible interactions pair-wise, it would be ridiculously impossible. Here we can look at thousands of combinations in an unbiased manner and pull out im-portant and powerful information. It gives us an unprecedented level of un-derstanding.”

Postdoctoral scholars Dan Xie, PhD; Alan Boyle, PhD; and Linfeng Wu, PhD, share first author credits on the paper. Together, they combined information from an international project called ENCODE (Encylopedia of DNA Elements) with their own ex-periments to come up with their findings:

They studied 128 proteins, called trans-acting factors, which are known to regulate gene ex-pression by binding to regulatory re-gions within the genome. Some of the regions control the expression of nearby genes; others affect the expression of genes great distances away.

The researchers used 238 data sets generated by the ENCODE project to study the specific DNA sequences bound by each of the 128 trans-acting factors. But these factors aren’t monogamous; they bind many different sequences in a variety of protein-DNA combinations.

Xie, Boyle and Snyder designed a ma-chine-learning algorithm to analyze all

the data and identify which trans-acting factors tend to be seen together and which DNA sequences they prefer.

Their technique allows re-searchers to track the dynam-ic interactions in living cells under a variety of conditions and discover new patterns, or new steps to this ongoing mo-

lecular dance and get us ever closer to the goal of personalized medicine for all.

“We’d like to understand how these interactions work together to make dif-ferent cell types and how they gain their unique identities in development,” Sny-der said. z

For more: http://tinyurl.com/ow-uu9cb.

5

BY EMILY HITE

To keep a patient healthy following an organ transplant, doctors must prescribe the right balance of immune-system-supress-ing drugs: The medications need to be strong enough to prevent rejection of the for-eign body but not leave the immune system at risk for infection. Now, a study by Stanford scientists has pin-pointed a little-known virus that spreads when these immunosup-pressant drugs take effect.

The anellovirus, first identified in 1997, could be a barometer of immune system strength, thereby informing more precise and less reactive treat-

ment for transplant recipients. Lead author Stephen Quake, PhD, and col-laborators isolated specific DNA frag-

ments floating in the blood plasma of 96 heart and lung transplant patients using a technique of genomics, of which Quake is a pioneer. The team studied how the drugs affected the body’s microbiome, or collection of bacteria, fungi and viruses.

As described in a release, the researchers found that “lower levels of anellovirus suggest a stron-ger immune system and an elevated risk of organ rejection, while higher levels of anellovirus suggest a weaker immune system with a corresponding

shift in risk toward vulnerability to in-fection.”

Hannah Valentine, MD, professor of cardiovascular medicine and senior as-sociate dean for diversity and leadership at the School of Medicine, remarked, “These findings suggest an effective tool to individualize the monitoring and, ulti-mately, the treatment of rejection. In the future, this could allow us to safely lower the doses of immunosuppressive drugs patients receive, thereby avoiding dev-astating side effects.” z

For more: http://tinyurl.com/mpt-guqw and http://tinyurl.com/onormvt.

Link to full article in Cell:

http://tinyurl.com/qg78t7n

Michael Snyder

Stephen Quake

Virus Could be Barometer of Immune System

Determining How Proteins Govern Genes

Link to full article in Cell:

http://tinyurl.com/pl8jmsp

46

The Stanford University School of Medicine was recently activated as a site for ixCell DCM trial and is current-ly recruiting patients.

This national randomized place-bo-controlled, double-blinded Phase II study aims to evaluate the bone marrow stem cell derivative, ixmye-locel-T, in subjects with ischemic car-diomyopathy. Ixmyelocel-T has been

shown to improve cardiac function in animals by promoting new blood ves-sel formation and reducing inflam-mation in the heart. Ixmyelocel-T has been shown to be safe in Phase I and IIa studies.

This study is sponsored by Aastrom Biosciences, Inc and has over 36 na-tional sites with over 10 subjects ran-domized in the trial. Joseph Wu, MD,

PhD, is the principle investigator for the Stanford site, and Drs. Patricia Nguyen and Karim Sallam are co-in-vestigators. They are all excited to bring state-of-the-art stem cell thera-py to Stanford patients.

For additional information about the trial, please contact the study coordinator, Edward Finn at efinn@stanford.edu or call (650) 724-6167.

Cardiovascular Institute’s Clinical Trial ManagerThe CVI welcomes Clinical Trials Manager Edward Finn.

He started in this role in March of 2013. Finn provides sup-port to CVI members and their interdisciplinary clinical trials research; this support includes re-cruitment, screening and consenting of patients, IRB submission, site initiation and monitoring visits, database management, budgeting, bill-ing, and overall study coordination.

Finn has a Master’s degree from San Francisco State University in Sport Science; his thesis work fo-cused on diabetes and cardiovascular disease. He has been working as a data analyst and research coordinator since 2005, having formerly worked at the VA, PAMF, Stanford University, and TempusClinic.

Finn is working with Dr. Ronald Dalman on a Medtronic PAN registry that is recruiting patients with Cardiac Rhyth-

mic disorders and recently opened a new arm to Cardio-vascular therapy (heart valves).

Finn is also working on 3 stem cell trials: 1) Dr. Phillip Yang and Dr. Nicholas Leeper’s PACE trial (associated with the CCTRN), which is recruiting PAD patients with intermittent claudication pain for treatment with ALDH bright cells; 2) Dr. Jo-seph Wu’s phase II Amorcyte Neostem trial, in-vestigating the preservation of cardiac function with autologous CD34+ stem cells for the treat-ment of acute MI; and 3) Dr. Joseph Wu’s phase IIb Aastrom trial, which is recruiting patients to investigate a treatment of chronic heart failure

with ixmyelocel –T stem cells.Edward Finn can contacted at efinn@stanford.edu or

(650) 724-6167.

Stanford Recruiting for ixCell DCM Trial

Edward Finn

The Cardiovascular Cell Therapy Research Network (CCTRN) is con-ducting an NIH-funded multi-center clinical trial to assess the benefits and risks of cell therapy in patients with peripheral arterial disease and clau-dication: The PACE trial (Patients with Intermittent Claudication Injected with ALDH Bright Cells).

PACE is a vascular stem cell clini-cal trial that will assess the potential physiologic effect, clinical efficacy, and safety of autologous bone mar-row derived aldehyde dehydroge-nase bright (ALDHBR) cells delivered by direct intramuscular injections to patients with atherosclerotic periph-eral arterial disease (PAD) and symp-

tom-limited intermittent claudication pain.

This trial involves an active treat-ment group and a placebo group (1:1 randomization ratio). All patients will undergo bilateral iliac crest bone mar-row harvest and have 10 intramus-cular injections (of cells or placebo solution) in the calf muscle and lower thigh. All patients will be followed for one year.

For more information regarding the PACE study, at Stanford University, and for details about patient criteria, please contact the Study Coordinator Fouzia Khan at (650) 736-1410 or at fouziak@stanford.edu.

If you or your colleagues would like to discuss this trial or the ther-apy in further detail, please call or email the study investigators listed below:

Nicholas Leeper, MD: (650) 724-8475 or nleeper@stanford.edu.

Phillip Yang, MD: (650) 498-8008 or phillip@stanford.edu.

For additional information on CCTRN visit: www.cctrn.org.

Stanford/CCTRN Recruiting for PACE Trial

CVI NewsBeatsEuan A. Ashley, MRCP, DPhil, has been promoted to Associate Pro-fessor of Medicine as of Sept. 1. Ashley also directs the Clinical Ge-nome Service, the Center for Inher-ited Cardiovascular Disease and the Hypertrophic Cardiomyopathy Center. For more: http://ashleylab.stanford.edu/.

Patricia Nguyen, MD, has been appointed Assistant Professor of Medicine (Cardiovascular Med-icine) at the Palo Alto Verterans Affairs Health Care System. She was previously an Instructor at VAPAHCS. For more: http://tinyurl.com/jw2ubpd.

Geoffrey C. Gurtner, MD, Associ-ate Professor of Surgery (Plastic and Reconstructive Surgery) will re-ceive about $3 million to work with a consortium to develop new treat-ments for wounded soldiers. The 5-year, $75 million federally funded project focuses on applying regen-erative medicine to battlefield inju-ries. For more: http://tinyurl.com/m2n8hvt.

Nicholas Leeper, MD, recently re-ceived two awards: The 2013 Jere-miah Stamler Distinguished Young Investigator Research Award ( given at the Northwestern Cardiovascular Young Investigators’ Forum); and a Stanford Translational Research and Applied Medicine (TRAM) pi-lot grant. For more: and http://tinyurl. com/m7ubqfl.

7

Venita Chandra, MD, has been ap-pointed to Clinical Assistant Pro-fessor effective Aug. 12. She will serve as Co-Medical Director of the Stanford Wound Care Center, open-ing May 2014 at the Stanford Medi-cine Outpatient Center in Redwood City. For more: http://tinyurl.com/la72kau.

George K. Lee, MD, has been ap-pointed to Clinical Assistant Pro-fessor (Affiliated) effective Sept. He will join the Vascular Surgery team at the Palo Alto Veterans Affairs Medical Center. For more: http://tinyurl.com/la72kau.

Mingxia Gu, PhD, postdoc in Jo-seph Wu’s lab, won a “Best Man-uscript Award” by the journal Cir-culation Research during the AHA Scientific Sessions 2013 held in Dal-las, Texas. The article was “Micro-fluidic Single-Cell Analysis Shows That Porcine Induced Pluripotent Stem Cell-Derived Endothelial Cells Improve Myocardial Function by Paracrine Activation”. For more: http://tinyurl.com/oqe2w5d.

Christopher Gardner, PhD, has been promoted to Professor (re-search) of Medicine, as of Nov. 1. He conducts research on nutrition and preventive medicine, with a particular focus on plant-based diets; cardiovascular disease; can-cer; and obesity. For more: http://tinyurl.com/kf4ym33.

CVI NewsBeatsMinang ‘Mintu’ Turakhia, MD, has been promoted to Assistant Pro-fessor of Medicine (Cardiovascular Medicine) at the Palo Alto Veter-ans Affairs Health Care System. He was a previously an Instructor at VAPAHCS. For more: http://tinyurl.com/k8onu2p.

8

Peter Chang (Nicholas Leeper Lab)Abstract: Socioeconomic Barriers to the Diagnosis of Pe-ripheral Arterial DiseaseMeeting: American Heart Association (AHA) Scientific Ses-sions 2013

Elizabeth Choe (James Spudich Lab)Abstract: S532P mutation in human β-cardiac myosin heavy chain decreases contractile force by decreasing the intrinsic force of the myosin motor.Meeting: AHA Scientific Sessions 2013

Michael Coronado (Daniel Bernstein Lab)Abstract: β1 vs β2-AR signaling differentially regulates mi-tochondrial dynamics through alterations in calcineurin and Drp1Meeting: Keystone Symposia – Mitochondrial Dynamics and Physiology

Fabian Emrich (Michael Fischbein Lab)Abstract: Apoptosis Participates in Early Aneurysm Devel-opment via ECM Remodeling in Marfan SyndromeMeeting: AHA Scientific Sessions 2013

Sang-Ging Ong (Joseph Wu Lab)Abstract: Transfer of Exosome-Enclosed MicroRNAs From Host Myocardial Cells to Transplanted Cardiac Stem Cells Facilitates Improved Survival in the Ischemic MyocardiumMeeting: AHA Scientific Sessions 2013

June-Wha Rhee (Francois Haddad Lab)Abstract: Elevated Right Ventricular Operant Diastolic Elastance Strongly Predicts Increased Risk of Mortality Following Heart TransplantationMeeting: AHA Scientific Sessions 2013

Anthony Sturzu (Sean Wu Lab)Abstract: A Novel Cell Ablation Strategy Defines the Regen-erative Potential of the Embryonic Mouse HeartMeeting: AHA Scientific Sessions 2013

Raiyan Zaman (Michael McConnell Lab)Abstract: Fiber-Optic Catheter System for Dual Optical Im-aging of Glucose Probes (18F-FDG and 6-NBDG) in Athero-sclerotic PlaquesMeeting: World Molecular Imaging Congress

October’s CVI Postdoctoral Travel Award Recipients

Thomas Rando, MD, PhD, profes-sor of neurology, and Tony Wyss-Coray, PhD, professor of neurology have received a $4.26 million award to explore the basis for physical activity’s robust positive effect o n cognitive function. For more: http://tinyurl.com/mz8hzuj.

CVI Members at the AHA Scientific SessionsThe 2013 AHA Scientific Sessions meeting took place in

Dallas, Texas this November. During the meeting CVI mem-bers presented 36 abstracts, 35 invited talks, 30 oral pre-sentations, and moderated 15 sessions. Five CVI members were also invited as discussants in panels and four poster professors.

Special thanks to Bob Harrington, MD, for his role as this year’s AHA program chair, and his opening remarks which kicked off the conference.

Selected CVI members that were honored during the AHA included: Vinicio de Jesus Perez, MD, who was recog-

nized as Fellow of the American Heart Association in 2013 by the 3CPR Committee; Marie-Helene Dziesietnik, PhD, Sr. Research Scientist in Daria Mochly-Rosen’s lab, whose poster was selected to be part of Late-Breaking Basic Sciences poster session; Marco Perez, MD, was a finalist for the FGTB Young Investigator Award; and Mingxia Gu, PhD, postdoc in Joseph Wu’s lab, won a “Best Manuscript Award” from the journal Circulation Research, presented during an event held at the AHA.

For a complete listing of CVI AHA participants please vis-it: http://tinyurl.com/q2ed8wl.

9

Co-Principle Investigators: Gerald Berry, MD; Curt Scharfe, MD, PhDCo-Investigators: Kitchener Wilson, MD, PhD; Justin Odegaard, MD, PhDA clinical-grade next generation sequencing assay for targeting DNA mutations in inherited non-syn-dromic cardiomyopathies

Principle Investigator: Alex Dunn, PhDCo-Principle Investigators: Gerald Fuller, PhD; Lorelei Shoemaker, PhD; Steven Chang, MDEndothelial cell fate specification in response to fluid flow

Principle Investigator: Susan Fernandes, LP.D., PA-CCo-Investigator: George Lui, MDRisk factors for acquired cardiovascular disease in adults with congenital heart disease

Co-Principle Investigators: Jason Lee, MD; Apurva Mehta, PhD; Drew Nelson, PhDA Novel Approach for Studying the Mechanical Behavior of Atherosclerotic Plaque

Principle Investigator: Nicholas Leeper, MDCo-Investigator: Andrew Connolly, MD, PhDThe paradoxical role of Cdkn2b in vessel sprouting and vessel maturation in athersosclerosis

Principle Investigator: Daria Mochly-Rosen, PhDCo-Principle Investigators: Daniel Bernstein, MD; Tobias Meyer, PhDIdentifying the master integrator of cardiac cell-fate decision

Principle Investigator: Beth Pruitt, PhDCo-Principle Investigator: Sean Wu, MD, PhDCo-Investigators: Euan Ashley, Dsc, PhD; Daniel Bernstein, MD; Alex Dunn, PhD; Kathy Ruppel, MD, PhD; James Spudich, PhDGenetic tracking and functional assessment of atrial- and ventricular-specific cardiomyoctyes from induced pluripotent stem cells

Principle Investigator: Sandra Tsai, MDCo-Investigators: Jennifer Tremmel, MD; Wes Alles, PhD; Katharine Sears, MDRandomized control trial to improve cardiovascular health in postpartum women diagnosed with pre-eclampsia

Recipients of the 2013 (FY14) CVI Seed Grants:

Photo: Nicholas Leeper Photo: Alexandre Ribeiro / Beth Pruitt Photo: Alexandre Ribeiro / Beth Pruitt

The Stanford Cardiovascular Institute (CVI) and Child Health Research Institute (CHRI) are pleased to announce the Recipients of the 2013 (FY14) CVI Seed Grants:

For more: http://tinyurl.com/outcu6h.

CVI Seed Grants

CVI Frontiers Seminars

10

11/26/2013Luiz Belardinelli, MDSenior Vice President of Cardiovascular Therapeutics at Gilead Sciences, Inc.

12/03/2013Norman Stockbridge, MD, PhDDirector, Office of Drug Evaluation I: Division of Cardiovascular and Renal Products, U.S. FDA

12/10/2013John M. Morton, MD, MPH, FACSAssociate Professor, General Surgery, Section Chief of Minimally Invasive Sur-gery, Stanford

12/17/2013Ali J. Marian, MDProfessor of Medicine, Texas Heart Institute

1/7/2014Judith S. Hochman, MDHarold Snyder Family Professor of Cardiol-ogy, Sr. Assoc Dean for Clinical and Transla-tional Med, Director Cardiovascular Clinical Research, New York University

1/14/2014Mark Hlatky, MDProfessor of Health Research and Policy and of Medicine (Cardiovascular), Stanford

1/21/2014Tony Muslin, MDExecutive Director, Head of Research, Cardiovascular and Metabolic Diseases (CVM), Novartis Institutes for BioMedical Research, Inc.

2/4/2014 Howard A. Rockman, MDProfessor of Medicine (Cardiology), Cell Biology, Molecular Genetics and Microbiology, Duke University Cardi-ology

2/25/2014Roger Hajjar, MDProfessor Medicine, Cardiology, Mount Sinai School of Medicine

3/4/2014 Mukesh Jain, MDDirector of the Case Cardiovascular Re-search Institute at Case Western Reserve University and the Ellery Sedgwick Jr. Chair & Distinguished Scientist University Hospitals-Case Medical Center

3/18/2014Jill Tardiff, MD, PhDProfessor of Medicine and Cellular and Molecular Medicine, Steven M. Gootter Endowed Chair for the Prevention of Sudden Cardiac Death, University of Arizona

12 noon to 1 p.m., Tuesdays Li Ka Shing Center Stanford School of Medicine 291 Campus Drive, Stanford, CA

The Cardiovascular Medicine Division and Cardiovascular Institute at Stanford University School of Medicine are seeking a faculty member at the Assistant, Associate, or Full Professor level to join the Cardiovascular Imaging Section. The individual must have advanced clinical and/or research experience, preferably in cardiovascular CT and multi-modality cardiovascular imaging, with a strong interest in advancing clinical research of new imaging methods, multi-center clinical trials, and compar-ative effectiveness/outcomes research.The position is for a full-time Medical Center Line (MCL) or University Tenure Line (UTL) faculty member. The major criteria for appointment for faculty in the MCL shall be excellence in the overall mix of clinical care, clinical teaching, scholarly activity that advances clinical medicine and institutional service appropriate to the programmatic needs the individual is expected to fulfill. Faculty rank will be determined by the qualifications and experience of the successful candidate. Individuals appointed as Assis-tant Professors will have completed their house staff training and postdoctoral fellowship training.The successful candidate is expected to develop an independently funded clinical/translational research program centered on cardiovascular imaging, and help with teaching activities in the Division and the Department of Medicine. Appropriate resources will be made available to help the applicant develop his/her research program.It is highly desirable that applicants have an MD degree and are board certified in Cardiovascular Disease (or eligible), and ad-vanced certification or training in cardiovascular imaging is highly desirable. However, exceptional PhD applicants will also be considered.Applicants should submit a curriculum vitae, a detailed letter of interest and the names of three referees to:

Michael V. McConnell, MD, MSEEProfessor of Medicine (Cardiovascular) andSearch Committee Chair, c/o Marisha Smithmarisha.smith@stanford.edu

Stanford University is an equal opportunity employer and is committed to increasing the diversity of its faculty. It welcomes nominations off and applications from women and members of minority groups, as well as others who would bring additional dimensions to the University’s research, teaching, and clinical missions.

Now Recruiting: Assistant/Associate/Full Professor in Cardiovascular ImagingStanford University

CVI PublicationsSept.: 99 publications

Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. Nature. Sep 22, 2013.

Usp16 contributes to somatic stem-cell defects in Down’s syn-drome. Adorno M, Sikandar S, Mitra SS, Kuo A, Nicolis Di Robi-lant B, Haro-Acosta V, Ouadah Y, Quarta M, Rodriguez J, Qian D, Reddy VM, Cheshier S, Garner CC, Clarke MF. Nature. 2013; 501(7467): 380-4.

The effects of excluding treatments from network meta-anal-yses: survey. Mills EJ, Kanters S, Thorlund K, Chaimani A, Ve-roniki AA, Ioannidis JP. BMJ. 2013;347: f5195.

Trends in adult emergency department visits in California by insurance status, 2005-2010. Hsia RY, Brownell J, Wilson S, Gordon N, Baker LC. JAMA. 2013; 310(11): 1181-3.

Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Taniguchi CM, Finger EC, Krieg AJ, Wu C, Diep AN, Lagory EL, Wei K, McGinnis LM, Yuan J, Kuo CJ, Giaccia AJ. Nat Med. Sep 15, 2013.

A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Wei K, Piecewicz SM, Mc-Ginnis LM, Taniguchi CM, Wiegand SJ, Anderson K, Chan CW, Mulligan KX, Kuo D, Yuan J, Vallon M, Morton LC, Lefai E, Si-mon MC, Maher JJ, Mithieux G, Rajas F, Annes JP, McGuinness OP, Thurston G, Giaccia AJ, Kuo CJ. Nat Med. 2013 Sep 15.

Early role for IL-6 signalling during generation of induced plu-ripotent stem cells revealed by heterokaryon RNA-Seq. Brady JJ, Li M, Suthram S, Jiang H, Wong WH, Blau HM. Nat Cell Biol. Sep 1, 2013.

Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardio-myopathy. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Circulation. 2013; 128 (11 Suppl 1): S42-9.

Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Sharma A, Bur-ridge PW, Patlolla B, Lee AS, Wu H, Beygui RE, Wu SM, Rob-bins RC, Bers DM, Wu JC. Circulation. 2013; 128(11 Suppl 1): S3-13.

Comparative effectiveness of multivessel coronary artery bypass graft surgery and multivessel percutaneous coronary intervention. Hlatky MA, Boothroyd DB. Ann Intern Med. 2013; 159(6): 435.

Hot Topics In Tetralogy Of Fallot. Villafañe J, Feinstein JA, Jen-kins KJ, Vincent RN, Walsh EP, Dubin AM, Geva T, Towbin JA, Cohen MS, Fraser C, Dearani J, Rosenthal D, Kaufman B, Gra-ham TP Jr. J Am Coll Cardiol. Sep 26, 2013.

Phosphofructokinase deficiency impairs ATP generation, auto-phagy, and redox balance in rheumatoid arthritis T cells. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. J Exp Med. 2013; 210(10): 2119-34.

Reliable Identification of Genomic Variants from RNA-Seq Data. Piskol R, Ramaswami G, Li JB. Am J Hum Genet. Sep 25, 2013.

Ly6d marks the earliest stage of B-cell specification and iden-tifies the branchpoint between B-cell and T-cell development. Inlay MA, Bhattacharya D, Sahoo D, Serwold T, Seita J, Kar-sunky H, Plevritis SK, Dill DL, Weissman IL. Genes Dev. 2013; 27(18): 2063.

Hemodynamic Regulation of Reactive Oxygen Species: Impli-cations for Vascular Diseases. Raaz U, Toh R, Maegdefessel L, Adam M, Nakagami F, Emrich FC, Spin JM, Tsao PS. Antioxid Redox Signal. Sep 17, 2013.

Myb promotes centriole amplification and later steps of the multiciliogenesis program. Tan FE, Vladar EK, Ma L, Fuenteal-ba LC, Hoh R, Espinoza FH, Axelrod JD, Alvarez-Buylla A, Stea-rns T, Kintner C, Krasnow MA. Development. Sept. 18, 2013.

Appropriate vs Clinically Useful Diagnostic Tests. Ioannidis JP. JAMA Intern Med. 2013; 173(17): 1607-9.

Effects of dimethylarginine dimethylaminohydrolase-1 over-expression on the response of the pulmonary vasculature to hypoxia. Bakr A, Pak O, Taye A, Hamada F, Hemeida R, Jans-sen W, Gierhardt M, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT, Witzenrath M, Brandes RP, Huang N, Cooke JP, Weissmann N, Sommer N. Am J Respir Cell Mol Biol. 2013; 49(3): 491-500.

Effect of a Telephone-Delivered Coronary Heart Disease Sec-ondary Prevention Program (ProActive Heart) on Quality of Life and Health Behaviours: Primary Outcomes of a Ran-domised Controlled Trial. Hawkes AL, Patrao TA, Atherton J, Ware RS, Taylor CB, O’Neil A, Foreman R, Oldenburg BF. Int J Behav Med. 2013; 20(3): 413-24.

11

For the complete list of September publications visit:http://cvi.stanford.edu/research/publications/sep13pubs.html

CVI PublicationsOct.: 101 publications

Discovery and refinement of loci associated with lipid levels. Global Lipids Genetics Consortium. Willer CJ, Schmidt EM, [+149 authors], Assimes TL, [+ 68 authors], Quertermous T, [+38 au-thors], Abecasis GR. Nat Genet. 2013; 45(11): 1274-83.

Common variants associated with plasma triglycerides and risk for coronary artery disease. Do R, Willer CJ, Schmidt EM, [+148 authors], Assimes TL, [+68 authors], Quertermous T, [+41 au-thors], Kathiresan S. Nat Genet. 2013; 45(11): 1345-52.

Extensive Variation in Chromatin States Across Humans. Kasowski M, Kyriazopoulou-Panagiotopoulou S, Grubert F, Zaugg JB, Kundaje A, Liu Y, Boyle AP, Zhang QC, Zakharia F, Spacek DV, Li J, Xie D, Olarerin-George A, Steinmetz LM, Ho-genesch JB, Kellis M, Batzoglou S, Snyder M. Science. Oct, 17, 2013.

A single-molecule long-read survey of the human transcrip-tome. Sharon D, Tilgner H, Grubert F, Snyder M. Nat Biotech-nol. Oct 13, 2013.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. Manson JE, Chlebowski RT, Stefanick ML, [+29 authors], Wallace RB. JAMA. 2013; 310(13): 1353-68.

Quantitative assessment of single-cell RNA-sequencing meth-ods. Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothen-berg ME, Mburu FM, Mantalas GL, Sim S, Clarke MF, Quake SR. Nat Methods. Oct 20, 2013.

Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. Basu S, Babiarz KS, Ebrahim S, Vellakkal S, Stuckler D, Goldhaber-Fiebert JD. BMJ. 2013; 347: f6048.

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and out-comes. Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, Hernandez AF, Hlatky MA, Luepker RV, Pe-terson PN, Reeves M, Smith EE. Circulation. 2013; 128(22): 2447-60.

Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syn-drome Patients Managed with or without In-Hospital Revascu-larization: A Substudy from the Prospective Randomized Plate-let Inhibition and Patient Outcomes (PLATO) Trial. Wallentin L, Lindholm D, Siegbahn A, [+ 6 authors], Harrington RA, Held

C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK. Circulation. 2013 Oct 29.

Assessing Intermediate Coronary Lesions: More than Meets the Eye. Fearon WF. Circulation. Oct 18, 2013.

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Mahaffey KW, Stevens SR, White HD, [+ 10 authors], Fox KA, Breithardt G; for the ROCK-ET AF Investigators. Eur Heart J. 2013 Oct 15.

Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanopar-ticles. Jiang X, Malkovskiy AV, Tian W, Sung YK, Sun W, Hsu JL, Manickam S, Wagh D, Joubert LM, Semenza GL, Rajadas J, Nicolls MR. Biomaterials. Oct 22, 2013.

Predicting the outcomes of rhabdomyolysis: a good starting point. Wilhelm-Leen ER, Winkelmayer WC. JAMA Intern Med. 2013; 173(19): 1828-9.

A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ trans-plantation. Khatri P, Roedder S, Kimura N, De Vusser K, Mor-gan AA, Gong Y, Fischbein MP, Robbins RC, Naesens M, Butte AJ, Sarwal MM. J Exp Med. 2013; 210(11): 2205-21.

The Critical Role of mRNA Destabilizing Protein Heterogeneous Nuclear Ribonucleoprotein D in 3’ Untranslated Region-Medi-ated Decay of Low-Density Lipoprotein Receptor mRNA in Liv-er Tissue. Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J. Arterioscler Thromb Vasc Biol. Oct. 24, 2013.

Does CHA2D2-VASc Improve Stroke Risk Stratification in Post-menopausal Women with Atrial Fibrillation? Abraham JM, Larson J, Chung MK, Curtis AB, Lakshminarayan K, Newman JD, Perez M, Rexrode K, Shara NM, Solomon AJ, Stefanick ML, Torner JC, Wilkoff BL, Wassertheil-Smoller S. Am J Med. Oct 17, 2013.

Robust pluripotent stem cell expansion and cardiomyocyte differentiation via geometric patterning. Myers FB, Silver JS, Zhuge Y, Beygui RE, Zarins CK, Lee LP, Abilez OJ. Integr Biol (Camb). 2013; 5(12): 1495-506.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM. Heart Rhythm. Oct. 10, 2013.

For the complete list of October publications visit:http://cvi.stanford.edu/research/publications/oct13pubs.html

12

Activation and allosteric modulation of a muscarinic acetyl-choline receptor. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Ei-tel K, Hübner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK. Nature. Nov. 20, 2013.

Stem cells: Differentiated cells in a back-up role. Desai TJ, Krasnow MA. Nature. 2013; 503(7475): 204-5.

Temporal response of the human virome to immunosuppres-sion and antiviral therapy. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR. Cell. 2013; 155(5): 1178-87.

High-performance silicon photoanodes passivated with ultra-thin nickel films for water oxidation. Kenney MJ, Gong M, Li Y, Wu JZ, Feng J, Lanza M, Dai H. Science. 2013; 342(6160): 836-40.

Patient-specific stem cells and cardiovascular drug discovery. Mordwinkin NM, Lee AS, Wu JC. JAMA. 2013; 310(19): 2039-40.

Quantifying RNA allelic ratios by microfluidic multiplex PCR and sequencing. Zhang R, Li X, Ramaswami G, Smith KS, Tu-recki G, Montgomery SB, Li JB. Nat Methods. Nov. 24, 2013.

Predicting the Future With Stem Cells. Mohsin S, Wu JC, Suss-man MA. Circulation. Nov. 18, 2013.

Endothelial Fate-Mapping in Mice with Pulmonary Hyperten-sion. Qiao L, Nishimura T, Shi L, Sessions D, Thrasher A, Trudell JR, Berry GJ, Pearl RG, Kao PN. Circulation. Nov. 7, 2013.

Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial. Whellan DJ, Tricoci P, Chen E, [+19 authors], Harrington RA, Mahaffey KW. J Am Coll Cardiol. Nov. 6, 2013.

Statins and cognitive function: a systematic review. Richard-son K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, Degoma EM. Ann Intern Med. 2013; 159(10): 688-97.

Protein microarray analysis reveals BAFF-binding autoanti-bodies in systemic lupus erythematosus. Price JV, Haddon DJ, Kemmer D, [+ 6 authors], Sokolove J, [+ 7 authors], Utz PJ. J Clin Invest. Nov. 25, 2013.

Association of β-Blocker Therapy With Risks of Adverse Car-

diovascular Events and Deaths in Patients With Ischemic Heart Disease Undergoing Noncardiac Surgery: A Danish Na-tionwide Cohort Study. Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA. JAMA Intern Med. Nov. 18, 2013.

Pathogenesis of Abdominal Aortic Aneurysms: MicroRNAs, Proteases, Genetic Associations. Maegdefessel L, Dalman RL, Tsao PS. Annu Rev Med. Nov. 21, 2013.

Characterization of the human ESC transcriptome by hybrid sequencing. Au KF, Sebastiano V, Afshar PT, Durruthy JD, Lee L, Williams BA, van Bakel H, Schadt EE, Reijo-Pera RA, Under-wood JG, Wong WH. Proc Natl Acad Sci USA. Nov. 26, 2013.

Immune mechanisms in medium and large-vessel vasculitis. Weyand CM, Goronzy JJ. Nat Rev Rheumatol. Nov. 5, 2013.

Costimulation-Adhesion Blockade is Superior to Cyclospo-rine A and Prednisone Immunosuppressive Therapy for Preventing Rejection of Differentiated Human Embryonic Stem Cells Following Transplantation. Huber BC, Ransohoff JD, Ransohoff KJ, Riegler J, Ebert A, Kodo K, Gong Y, San-chez-Freire V, Dey D, Kooreman NG, Diecke S, Zhang WY, Ode-gaard J, Hu S, Gold JD, Robbins RC, Wu JC. Stem Cells. 2013; 31(11): 2354-63.

Heart and Combined Heart-Kidney Transplantation in Pa-tients With Concomitant Renal Insufficiency and End-Stage Heart Failure. Schaffer JM, Chiu P, Singh SK, Oyer PE, Reitz BA, Mallidi HR. Am J Transplant. Nov. 26, 2013.

Outcomes of Transcatheter and Surgical Aortic Valve Replace-ment in High-Risk Patients With Aortic Stenosis and Left Ven-tricular Dysfunction: Results From the Placement of Aortic Transcatheter Valves (PARTNER) Trial (Cohort A). Elmariah S, Palacios IF, McAndrew T, Hueter I, Inglessis I, Baker JN, Kodali S, Leon MB, Svensson L, Pibarot P, Douglas PS, Fearon WF, Kir-tane AJ, Maniar HS, Passeri JJ; on behalf of the PARTNER Inves-tigators. Circ Cardiovasc Interv. Nov. 12, 2013.

Gaps in preoperative surveillance and rupture of abdominal aortic aneurysms among Medicare beneficiaries. Mell MW, Baker LC, Dalman RL, Hlatky MA. J Vasc Surg. Nov. 16, 2013.

Variation in use of left ventriculography in the veterans af-fairs health care system. Heidenreich PA, Lin S, Knowles JW, Perez M, Maddox TM, Ho MP, Rumsfeld JS, Sahay A, Massie BM, Tsai TT, Witteles RM. Circ Cardiovasc Qual Outcomes. 2013; 6(6): 687-93.

CVI PublicationsNov.: 83 publications For the complete list of November publications visit:

http://cvi.stanford.edu/research/publications/nov13pubs.html

13

DECEMBERNational Institute of HealthDirector’s Early Independence Award$250,000/year for 5 yearsDecember 16, 2013

American Federation for Aging ResearchEllison Medical Foundation / AFAR Postdoctoral Fellows in Aging Re-search Program$47,114 to $55,670 for 1 yearLOI: December 16, 2013

JANUARYThe International Society for Heart & Lung Transplantation

Branislav Radovancevic Memorial Fellowship$75,000 over 1 yearsJanuary 15, 2014 Research Fellowship Award$40,000 over 1 yearsJanuary 15, 2014

American Heart Association

Mentored Clinical and Population Research$140,000 over 2 yearsJanuary 16, 2014

Mentored Clinical and Population Research Award$100,000 over 2 yearsJanuary 16, 2014

National Fellow-to-Faculty Transi-tion Award$132,000 over 5 yearsJanuary 17, 2014

National Scientist Development Grant$308,000 over 4 yearsJanuary 17, 2014

FEBRUARYMarfan Foundation Victor A. McKusick Fellowship Program$50-75K over 2 yearsFebruary 1, 2014

Stanford Cardiovascular InstituteCVI Postdoctoral Fellow Travel Award$750 per award February 1, 2014

Stanford Child Health Research Institute (CHRI)CHRI Clinical Trainee Support$100,000February 1, 2014

National Institute of Health

K01 Mentored Career Development Award to Promote Faculty Diversi-ty/Re-Entry in Biomedical ResearchFebruary 7, 2014

K99/R00 NIH Pathway to Indepen-dence AwardFebruary 12, 2014

K08 Mentored Clinical Research Career Development AwardFebruary 12, 2014

K23 Mentored Patient-Oriented Re-search Career Development AwardFebruary 12, 2014

MARCHThrasher Research FundEarly Career Awards $25K over 2 yearsMarch 17, 2014

Stanford Cardiovascular InstituteMyocardial Biology (T32)March 15, 2014

Mechanisms and Innovation in Vas-cular Disease (T32)March 15, 2014

Upcoming GrantsDECEMBER

Muscular Dystrophy Association Re-search Grants & Development Grants$60,000/yearLOI: December 15, 2013

JANUARYCalifornia Institute for Regenerative Medicine (CIRM)RFA 13-05: CIRM Tools and Technolo-gies III Awards$900-1,200K over 3 yearsJanuary 7, 2014

The International Society for Heart & Lung Transplantation Norman E. Shumway Career Devel-opment Award $160,000 over 2 yearsJanuary 15, 2014

American Heart AssociationBeginning-Grant-in-Aid$140,000 over 2 yearsJanuary 16, 2014

Grant-in-Aid$140,000 over 2 yearsJanuary 16, 2014

Donald E. and Delia B. Baxter Foun-dation2014 Faculty Scholar ProgramJanuary 27, 2014

National Institute of Health Director’s Early Independence Award (DP5)January 31, 2014

APRILMarfan FoundationEarly Investigator Grant Program$75,000 over 2 yearsApril 14, 2014

Postdoctoral & Pre-doctoral Awards

14

15

Li Ka Shing Center for Learning & Knowledge291 Campus Drive, Stanford, CA 94305

SAVE THE

DATEFEBRUARY 28

2014CardiovascularRegenerative Medicine Symposium

Photo: Linda A. Cicero, Stanford News Service

JANUARYConference on Cell Therapy for Car-diovascular DiseaseJanuary 22 – 24, 2014New York, NY

Keystone Symposia - New Frontiers in the Discovery and Treatment of Thrombosis (A6) January 26 – 30, 2014 Keystone, Colorado, USA

Keystone Symposia -- Growth and Wasting in Heart and Skeletal Mus-cleJanuary 26 – 31, 2014 Santa Fe, New Mexico, USA

European Society of Cardiology - Rome Cardiology Forum 2014January 29 – 31, 2014Rome, Italy

Peripheral Vascular Surgery SocietyJanuary 30 – February 2, 2014Steamboat Springs, CO

FEBRUARYInternational Stoke ConferenceFebruary 12 – 14, 2014San Diego, CA

Annual Stanford CVI Symposium: Cardiovascular Regenerative Med-icineFebruary 28, 2014Stanford, CA

MARCHAHA Epidemiology and Prevention & Nutrition, Physical Activity and Metabolism (EPI/NPAM)March 18 – 21, 2014San Francisco, CA

Society for Clinical Vascular Surgery Annual SymposiumMarch 18 – 22, 2014Carlsbad, CA

Cardiovascular Research Foun-dation - Coronary Physiology and Intravascular Imaging SymposiumMarch 27 – 28, 2014Washington, DC

American College of Cardiology (ACC) Meeting March 29 – 31, 2014Washington, DC

APRILCardiovascular Research Foundai-ton -- Annual Echocardiography ConferenenceApril 3 – 5, 2014New York, NY

Upcoming Meetings

16

Tom Quertermous Alan Yeung

Ronald Dalman Philip OyerDominik Fleischmann

Robert Harrington

Cardiovascular Institute LeadershipJoseph C. Wu, MD, PhDDirector, Stanford Cardiovascular Institute Professor, Dept. of Medicine (Cardiovascular) and Radiology

Joseph Wu

Kenneth Mahaffey

Stephen Roth

Mark Nicolls

Michael Snyder

Robert A. Harrington, MDArthur L. Bloomfield Professor of Medicine

Chair, Dept. of Medicine

Marlene Rabinovitch

Paul Yock

Ronald L. Dalman, MDWalter C. and Elsa R. Chidester Professor of SurgeryChief, Division of Vascular SurgeryDominik Fleischmann, MDProfessor, Dept. of RadiologyChief, Cardiovascular ImagingKenneth Mahaffey, MDProfessor, Dept. of MedicineVice Chair of Medicine for Clinical ResearchMark Nicolls, MDAssociate Professor, Dept. of MedicineChief, Pulmonary and Critical Care MedicinePhilip E. Oyer, MD, PhDRoy B. Cohn-Theodore A. Falasco ProfessorInterim Chair, Dept. of CardiothoracicSurgeryTom Quertermous, MDWilliam G. Irwin Professor of MedicineCo-Chief (Research), Division of Cardiovas-cular Medicine

Marlene Rabinovitch, MDDwight and Vera Dunlevie Professor inPediatric Cardiology

Stephen J. Roth MD, MPHProfessor and Chief, Pediatric CardiologyDirector, Children’s Heart Center

Michael Snyder, PhDProfessor and Chair, Dept. of GeneticsDirector, Stanford Center for Genomics and Personalized Medicine

Alan Yeung, MDLi Ka Shing Professor of MedicineCo-Chief (Clinical), Division of Cardiovascu-lar Medicine

Paul Yock, MDMartha Meier Weiland Professor of Bioen-gineering and Medicine; and Professor, by courtesy, of Mechanical EngineeringDirector of Biodesign